Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Drug

Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...

Company Drug

CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment

Fineline Cube May 5, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir

Fineline Cube May 5, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the completion of 1,200 patient...

Company

BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans

Fineline Cube May 5, 2023

China-based BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has reported financial results for the...

Policy / Regulatory

China’s Regulatory Bodies Unveil Guidelines to Strengthen Supervision of Medical Aesthetic Industry

Fineline Cube May 5, 2023

The State Administration for Market Regulation, National Health Commission, National Administration of Traditional Chinese Medicine,...

Company Deals

Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University

Fineline Cube May 4, 2023

Harbin Medisan Pharmaceutical Co., Ltd (SHE: 002900) has announced a significant patent and technology transfer...

Company

Meihua International Medical Expands with New Healthcare Industrial Park in Hainan

Fineline Cube May 4, 2023

Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...

Company Drug

Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial

Fineline Cube May 4, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...

Company Drug

BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial

Fineline Cube May 4, 2023

Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...

Company Drug

SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301

Fineline Cube May 4, 2023

SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...

Company Drug

Qilu Pharmaceutical Launches First Generic Iressa in the US Market

Fineline Cube May 4, 2023

China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...

Company Deals

NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments

Fineline Cube May 4, 2023

NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases,...

Company Drug

Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study

Fineline Cube May 4, 2023

Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...

Company Drug

TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases

Fineline Cube May 4, 2023

Shanghai-based TYK Medicines has announced that it has received the green light from the Center...

Policy / Regulatory

NMPA Transitions Desloratadine, Loratadine, Ambroxol, and Naproxen to OTC Status

Fineline Cube May 4, 2023

The National Medical Products Administration (NMPA) has indicated on its website that four products will...

Company Drug

Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies

Fineline Cube May 4, 2023

Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...

Company Deals

Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies

Fineline Cube May 4, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...

Policy / Regulatory

Chinese Authorities Launch Special Campaign to Combat Fraud in Medical Insurance

Fineline Cube May 4, 2023

The National Healthcare Security Administration, Supreme People’s Procurator, Ministry of Public Security, Ministry of Finance,...

Company Deals

Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO

Fineline Cube May 4, 2023

US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering...

Company

Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region

Fineline Cube May 4, 2023

Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region...

Posts pagination

1 … 508 509 510 … 644

Recent updates

  • Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic
  • Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
  • Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.